MichaelJRamirezMD

PubMed

• 1 citations
  Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
  Jonathan Pan, Sushil Ghimire, S. Onder Alpdogan, Andrew E. Chapman, Matthew Carabasi, Martina DiMeglio, Jerald Z. Gong, Ubaldo E. Martinez-Outschoorn, Lewis J. Rose, M...> ;Leukemia & Lymphoma. 2021 Feb 23
• 72 citations
  Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
  Gregory J. Kubicek, Maria Werner-Wasik, Mitchell Machtay, Gayle Mallon, Thomas J. Myers, Michael J. Ramirez, David W. Andrews, Walter J. Curran, Adam P. Dicker> ;International Journal of Radiation Oncology, Biology, Physics. 2009 Jun 1
• 78 citations
  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy
  Lyndsay Harris, Vlayka Liotcheva, Gloria Broadwater, Michael J. Ramirez, Peter Maimonis, Steven Anderson, Tajuana Everett, David H. Harpole, Mary Beth Moore, Donald A....> ;Journal of Clinical Oncology. 2001 Mar 15
• 3 citations
  Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer
  K. A. Havlin, Michael J. Ramirez, Christine M. Legler, Lydsay N. Harris, Ursula A. Matulonis, John A. Hohneker, Daniel F. Hayes, Eric P. Winer> ;Cancer Chemotherapy and Pharmacology. 1999 Jan 1
• Join now to see all